Latest News From Lumira Ventures

Aurinia Partners with National Kidney Foundation on Awareness Initiative

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced new initiatives to support the lupus nephritis (LN) community …

New Data Confirms Cardiac Dimensions’ Carillon® System Shows Favorable Long-Term Survival Rate In Patients

Jennifer Schram Cardiac Dimensions, Portfolio News, Press Release

KIRKLAND, Wash. — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the findings of a post hoc analysis of pooled prospectively collected data from three …

Aurinia Appoints New Chief Commercial Officer & Expands U.S. Leadership

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the appointment of Max Colao to the newly created position of Chief Commercial …

Antios Therapeutics Initiates First-in-Human Phase 1 Study of ATI-2173

Jennifer Schram Antios Therapeutics, Portfolio News, Press Release

ATLANTA /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase 1 clinical trial for ATI-2173, a novel liver-targeted, orally-administered, …